Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Spinal fluid clues may reveal brain recovery secrets

NCT ID NCT07600996

Knowledge-focused Sponsor: Capital Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 10, 2026 · Updated 2 times

Summary

This study is observing tiny energy-producing parts of cells, called mitochondria, in the spinal fluid of people who have had a stroke or have Alzheimer's disease. Researchers want to see if these markers relate to how well patients recover after a stroke. The study does not give any treatment—it only uses leftover fluid from routine medical tests.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help identify new ways to measure brain damage or recovery after stroke and Alzheimer's disease.
What could go wrong
This is a small, early observational study with only 40 participants. It does not test any treatment, so results may not lead to immediate changes in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

40 people

The number who actually took part.

Started

Mar 2026

Finished

Aug 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will include adult patients treated at Xuanwu Hospital, Capital Medical University between March 2026 and May 2026 who are diagnosed with ischemic stroke or Alzheimer disease and require diagnostic lumbar puncture for clinical indications. Only patients with available residual cerebrospinal fluid after completion of routine clinical testing will be included.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or older. Patients treated at Xuanwu Hospital, Capital Medical University between March 2026 and May 2026. Diagnosis of ischemic stroke or Alzheimer disease according to standard clinical diagnostic criteria. Diagnostic lumbar puncture performed for clinical indications as part of routine medical care. Availability of residual cerebrospinal fluid after completion of clinically required testing. Ability to provide written informed consent, or availability of a legally authorized representative to provide consent when appropriate. For ischemic stroke patients, availability of baseline neurological assessment and planned follow-up for 90-day modified Rankin Scale assessment. Exclusion Criteria: * Lumbar puncture performed solely for research purposes rather than clinical indication. Insufficient residual cerebrospinal fluid volume for research flow cytometry analysis. Grossly bloody or severely contaminated cerebrospinal fluid sample that precludes reliable flow cytometry analysis. Known central nervous system infection, malignant meningitis, or other inflammatory or neoplastic condition that, in the investigator's judgment, may substantially confound cerebrospinal fluid mitochondrial measurements. Inability to obtain informed consent from the participant or legally authorized representative. Missing key clinical outcome data, including admission NIHSS, discharge NIHSS, or planned 90-day mRS follow-up for ischemic stroke participants. Any condition judged by the investigator to make the participant unsuitable for inclusion in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer disease (AD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Alzheimer disease ischemic stroke

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alzheimer disease (AD) Ischemic stroke

Contacts and locations

Locations

  • Xuanwu Hospital

    Beijing, None Selected, 100053, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.